Trexquant Investment’s KalVista Pharmaceuticals KALV Stock Holding History

Trexquant Investment’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.81M	Buy	+139,458	New	+$2.25M	0.02%	868
2025 Q3	–	Sell	-12,781	Closed	-$144K	–	1750
2025 Q2	$144K	Buy	+12,781	New	+$156K	﹤0.01%	1467
2024 Q2	–	Sell	-55,444	Closed	-$658K	–	1695
2024 Q1	$658K	Buy	+55,444	New	+$739K	0.01%	1066
2022 Q3	–	Sell	-39,048	Closed	-$384K	–	1626
2022 Q2	$384K	Buy	+39,048	New	+$431K	0.02%	989
2022 Q1	–	Sell	-17,131	Closed	-$227K	–	1548
2021 Q4	$227K	Sell	17,131 -2,007	-10%	-$31.9K	0.01%	1077
2021 Q3	$334K	Buy	+19,138	New	+$388K	0.03%	697
2020 Q3	–	Sell	-13,169	Closed	-$159K	–	1380
2020 Q2	$159K	Buy	+13,169	New	+$140K	0.01%	1075
2019 Q4	–	Sell	-15,799	Closed	-$183K	–	1154
2019 Q3	$183K	Buy	+15,799	New	+$255K	0.02%	766

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Trexquant Investment's KALV Position: Q1 2026 in Review

Trexquant Investment opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 139,458 shares worth $2.81M. The stake represents 0.02% of the portfolio and ranks #868 among its holdings. This is a return to the name: Trexquant Investment previously reported a position in KALV as recently as Q2 2025.

Trexquant Investment first reported a position in KALV in Q3 2019 and has held it in 8 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Trexquant Investment held 139,458 shares of KalVista Pharmaceuticals worth $2.81M as of Q1 2026.
KalVista Pharmaceuticals was a new Trexquant Investment position in Q1 2026.
KalVista Pharmaceuticals made up 0.02% of Trexquant Investment's portfolio in Q1 2026, its #868 holding.
Trexquant Investment first reported a position in KalVista Pharmaceuticals in Q3 2019 and has held it in 8 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.